Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

The Lancet

Volumn 378, Issue 9790, 2011, Pages 487-497

  Sherry, Nicole ^a   Hagopian, William ^b   Ludvigsson, Johnny ^c   Jain, Sunil M ^d   Wahlen, Jack ^e   Ferry Jr , Robert J ^f   Bode, Bruce ^g   Aronoff, Stephen ^h   Holland, Christopher ⁱ   Carlin, David ⁱ   King, Karen L ⁱ   Wilder, Ronald L ^j   Pillemer, Stanley ^k   Bonvini, Ezio ⁱ   Johnson, Syd ⁱ   Stein, Kathryn E ⁱ   Koenig, Scott ⁱ   Herold, Kevan C ^l   Daifotis, Anastasia G ⁱ  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^c LINKÖPING UNIVERSITY   (Sweden)

^d TOTALL Diabetes Hormone Institute   (India)

^e Endocrine Research Specialists   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g ATLANTA DIABETES ASSOCIATES   (United States)

^h Research Institute of Dallas   (United States)

ⁱ Analytical Sciences   (United States)

^j PAREXEL INTERNATIONAL   (United States)

^k American Biopharma Corporation   (United States)

^l YALE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; PLACEBO; TEPLIZUMAB;

ABDOMINAL PAIN; ABSCESS; ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAL ABSCESS; ANEMIA; APPENDICITIS; AREA UNDER THE CURVE; ARTICLE; BICARBONATE BLOOD LEVEL; BRONCHITIS; CELIAC DISEASE; CELLULITIS; CHILD; CHILL; CONTROLLED STUDY; CORNEA EROSION; CYTOKINE RELEASE SYNDROME; DEHYDRATION; DEPRESSION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; EPIDIDYMITIS; FATIGUE; FEMALE; FEVER; GASTRITIS; GASTROENTERITIS; HEADACHE; HEPATOBILIARY DISEASE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERSENSITIVITY; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOGLYCEMIC COMA; HYPOGLYCEMIC SEIZURE; HYPOKALEMIA; HYPONATREMIA; INFECTION; INJURY; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE OBSTRUCTION; INTOXICATION; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL CHEST PAIN; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OROPHARYNGEAL PAIN; PAIN; PARONYCHIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SCHOOL CHILD; SCREENING TEST; SEIZURE; SIDE EFFECT; SODIUM BLOOD LEVEL; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULOSIS; UNCONSCIOUSNESS; UPPER EXTREMITY DEEP VEIN THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTRITIS; VIRAL GASTROENTERITIS; VOMITING;

EID: 80051471700     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60931-8     Document Type: Article

References (21)

1. TL van Belle, KT Coppieters, MG von Herrath Type 1 diabetes: etiology, immunology, and therapeutic strategies Physiol Rev 91 2011 79 118
2. C Steele, WA Hagopian, S Gitelman et al. Insulin secretion in type 1 diabetes Diabetes 53 2004 426 433 (Pubitemid 38174559)
3. NA Sherry, JA Kushner, M Glandt, T Kitamura, AM Brillantes, KC Herold Effects of autoimmunity and immune therapy on β-cell turnover in type 1 diabetes Diabetes 55 2006 3238 3245 (Pubitemid 44923579)
4. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
5. Diabetes Prevention Trial - Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus N Engl J Med 346 2002 1685 1691
6. J Ludvigsson, M Faresjö, M Hjorth et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes N Engl J Med 359 2008 1909 1920
7. J Silverstein, G Klingensmith, K Copeland et al. Care of children and adolescents with type 1 diabetes Diabetes Care 28 2005 186 212
8. X Luo, KC Herold, SD Miller Immunotherapy of type 1 diabetes: where are we at and where should we be going? Immunity 32 2010 488 499
9. B Keymeulen, M Walter, C Mathieu et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass Diabetologia 53 2010 614 623
10. L Chatenoud Immune therapy of autoimmune diabetes: what is unique with CD3 antibodies? Nat Rev End 6 2010 149 157
11. D Xu, M-L Alegre, SS Varga et al. In vitro characterization of five humanized OKT3 effector function variant antibodies Cellular Immunol 200 2000 16 26 (Pubitemid 30170076)
12. KC Herold, W Hagopian, JA Auger et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 346 2002 1692 1698 (Pubitemid 34547482)
13. B Keymuelen, E Vandemeulebroucke, AG Zeigler et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes N Engl J Med 352 2005 2598 2608 (Pubitemid 41007846)
14. B Keymeulen, S Candon, S Fafi-Kremer et al. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients Blood 115 2009 1145 1155
15. PR Newswire Tolerx and GlaxoSmithKline announce phase 3 defend-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint http://www.prnewswire.com/news-releases/tolerx-and-glaxosmithkline-announce- phase-3-defend-1-study-of-otelixizumab-in-type-1-diabetes-did-not-meet-its- primary-endpoint-117795473.html (accessed June 9, 2011).
16. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 29 2006 S43 S48
17. S Holm A simple sequentially rejective multiple test procedure Scand J Stat 6 1979 65 70
18. GY Gandhi, MH Murad, DN Flynn et al. Immunotherapeutic agents in type 1 diabetes: a systematic review and meta-analysis of randomized trials Clin Endocrinol (Oxf) 69 2008 244 252 (Pubitemid 352009018)
19. TL van Belle, KT Coppieters, MG von Herrath Type 1 diabetes: etiology, immunology, and therapeutic strategies Physiol Rev 91 2011 79 118
20. S Bolt, E Routledge, I Lloyd et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties Eur J Immunol 23 1993 403 411 (Pubitemid 23075070)
21. EvaluatePharma Tolerx presents otelixizumab phase 2 dose optimization data at the IDF's 20th World Diabetes Congress http://www.evaluatepharma.com/ Universal/View.aspx?type=Story&id=224944 (accessed June 20, 2011).